ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts.
Quigley
Neil B
NB
Henley
Donald C
DC
Hubbard
Roger A
RA
Laudadio
Jennifer
J
Press
Richard D
RD
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D005091:Exons / Q000235:genetics*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics; D016254:Mutagenesis, Insertional; D010770:Phosphotransferases / Q000737:chemistry* / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use; D017434:Protein Structure, Tertiary / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use; D014158:Transcription, Genetic
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D010770:Phosphotransferases; D016044:Fusion Proteins, bcr-abl